Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Date:3/11/2009

ed.com/" target="_new">www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that closing conditions under our agreement with Merck & Co., Inc. may not be met, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for MMD may not actually match up with our external assessment, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this r
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Bioptigen announced today the availability ... the optical device metrology and pre-clinical ophthalmic research markets. ... for Contact Lens Metrology is designed for non-destructive, non-contact, ... lens, IOL structures, and donor tissues. The ... immersed in a hydration bath (saline), automated segmentation of ...
(Date:9/15/2014)... Research and Markets has announced the ... by Services, by Technology, by Application - Global Forecast to ... Exome Sequencing (WES) is next-generation technology used for strategically sequencing ... exome, which is the total of all exons of an ... actually converted into proteins after translation. It is responsible for ...
(Date:9/15/2014)... Die zweite jährliche International Plasma ... 18. Oktober stattfinden. Die IPAW ist eine gemeinsame ... (PPTA) und ihrer Mitgliedsunternehmen und hat ... für die Gewinnung von Quellplasma zu steigern ... Verbessern von Leben zu würdigen , Das ...
(Date:9/15/2014)... , Sept. 15, 2014  The second annual ... celebrated October 12-18. A joint initiative of the ... member companies , IPAW is designed to: ... , Recognize the contributions of plasma donors in saving ... plasma protein therapies and rare diseases ...
Breaking Biology Technology:Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 2International Plasma Awareness Week feiert Spender und rückt seltene Krankheiten in den Mittelpunkt 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... 6 CryoLife, Inc., (NYSE: ... processing company, today announced that it has received a Humanitarian ... (FDA) for its CryoValve® SG aortic human heart valve. ... Humanitarian Device Exemption (HDE) for the CryoValve SG aortic human ...
... , PALO ALTO, Calif., Oct. 6 Varian, Inc. (NasdaqGS: VARI) ... October 5, 2009, its stockholders adopted the merger agreement entered ... Varian for $52.00 per share in cash. Approximately 84% ... August 12, 2009, the record date for the special meeting, ...
... ... today announced its sole focus of delivering novel nanotechnology solutions for instantly assessing ... world, without requiring a costly, complex medical infrastructure. , ... Santa Barbara, CA (PRWEB) October ...
Cached Biology Technology:CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 2Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 3Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate 4
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
(Date:9/15/2014)... When this week,s print issue of the journal ... up from New Mexico, Montana and even the Netherlands, ... more and more the norm in these connected times. ... it will produce innovations in biology, medicine, biotechnology and ... this scientist talked with that one, that one knew ...
(Date:9/15/2014)... A new strategic vision document, released today by ... describes the long-term goals, objectives, and strategies for ... work over the next five years (2015-2020). ... short-term activities, to be funded in 2015, will ... policy fellowships. , The $500 million, 30-year ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Collaboration drives achievement in protein structure research 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... researchers have proved that eating strawberries reduces the harm ... Published in the open access journal Plos One, the ... ulcers. A team of Italian, Serbian and Spanish ... in a mammal stomach that has been damaged by ...
... of a brain protein that regulates gene expression may play ... and sometimes disabling psychiatric disease. As reported in the latest ... International Society for Bipolar Disorders, levels of SP4 (specificity protein ... in postmortem samples from patients with bipolar disorder. The study ...
... latest issue of Elsevier,s Materials Today , researchers ... of carbon nanotubes to create mechanical components for use ... industry has excelled in miniaturizing components, with individual elements ... reducing the size of mechanical systems has proved much ...
Cached Biology News:Strawberries protect the stomach from alcohol 2Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3Nanotubes key to microscopic mechanics 2
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
... 2000 One-Step FP Standardization Kit is ... low fluorescence polarization values of fluorescein ... Beacon 2000 System. It also allows ... generated by their instrument to the ...
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
Biology Products: